AI English summary of an SEC filing — figures as filed
Henry Schein HSICHenry Schein said second-quarter Q2 2025 GAAP diluted EPS was $0.70, compared to $0.80 in Q2 2024, non-GAAP diluted EPS was $1.10, compared to $1.23 in Q2 2024, and Adjusted EBITDA was $256 million, compared to $268 million in Q2 2024.
Key points
AI summaryHenry Schein said second-quarter Q2 2025 GAAP diluted EPS was $0.70, compared to $0.80 in Q2 2024, non-GAAP diluted EPS was $1.10, compared to $1.23 in Q2 2024, and Adjusted EBITDA was $256 million, compared to $268 million in Q2 2024.
The company said total net sales for Q2 2025 were $3.2 billion, with as-reported total net sales increasing 3.3%, reflecting 1.9% internal sales growth, 0.8% sales growth from acquisitions, and 0.6% from foreign currency exchange. By segment, the company cited Global Medical Distribution sales increased 6.1%, Global Technology sales increased 7.4%, and Global Specialty Products sales increased 4.2%.
Henry Schein said during Q2 2025 it repurchased approximately 3.7 million shares of common stock at an average price of $70.88 per share for a total of $259 million. It said this included approximately 3.1 million shares under its Accelerated Stock Repurchase plan at an average price of $223 million per share, which followed the company's sale of 3.3 million shares of common stock at an average price of $250 million per share to KKR.
Henry Schein maintained its 2025 non-GAAP diluted EPS guidance of $4.80 to $4.94, total sales growth of approximately 2% to 4%, and Adjusted EBITDA growth of mid-single digits. The company said restructuring costs recorded in Q2 were $23 million and it expects to achieve annual run-rate savings of over $100 million by the end of 2025.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q2 GAAP and non-GAAP diluted EPS and Adjusted EBITDA
Henry Schein said second-quarter Q2 2025 GAAP diluted EPS was $0.70, compared to $0.80 in Q2 2024, non-GAAP diluted EPS was $1.10, compared to $1.23 in Q2 2024, and Adjusted EBITDA was $256 million, compared to $268 million in Q2 2024.
Source · Based on the filing body and exhibits
Q2 sales of $3.2 billion and segment growth
The company said total net sales for Q2 2025 were $3.2 billion, with as-reported total net sales increasing 3.3%, reflecting 1.9% internal sales growth, 0.8% sales growth from acquisitions, and 0.6% from foreign currency exchange. By segment, the company cited Global Medical Distribution sales increased 6.1%, Global Technology sales increased 7.4%, and Global Specialty Products sales increased 4.2%.
Source · Based on the filing body and exhibits
Q2 share repurchases of $259 million and stock sale to KKR
Henry Schein said during Q2 2025 it repurchased approximately 3.7 million shares of common stock at an average price of $70.88 per share for a total of $259 million. It said this included approximately 3.1 million shares under its Accelerated Stock Repurchase plan at an average price of $223 million per share, which followed the company's sale of 3.3 million shares of common stock at an average price of $250 million per share to KKR.
Source · Based on the filing body and exhibits
2025 guidance maintained and restructuring costs
Henry Schein maintained its 2025 non-GAAP diluted EPS guidance of $4.80 to $4.94, total sales growth of approximately 2% to 4%, and Adjusted EBITDA growth of mid-single digits. The company said restructuring costs recorded in Q2 were $23 million and it expects to achieve annual run-rate savings of over $100 million by the end of 2025.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…